Orthofix Q2 net sales $210.9M (+5% constant currency); raises FY2026 guidance

Orthofix Medical Inc.

Q2 net sales $210.9M, up 5% pro forma constant currency YoY; GAAP net loss $(15.8)M ($0.39 loss per share).
Non-GAAP adjusted EBITDA $20.1M (9.6% of sales) vs $20.6M (10.3%) prior year; margin slightly down.
Raised FY2026 net sales guidance to $845M-$855M (from $838M-$848M) and adjusted EBITDA to $95M-$98M (from $90M-$93M).
Global Limb Reconstruction grew 11% constant currency; Spine Fixation double-digit; Biologics stabilizing.
Cash $104.4M, down from $120.9M due to arbitration payments to former executives.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.